Abstract: Obesity Medicine 19 (2020) 100290 Contents lists available at ScienceDirect Obesity Medicine journal homepage: www.elsevier.com/locate/obmed Short communication Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection Timotius Ivan Hariyanto a, Andree Kurniawan b, * a b Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia A R T I C L E I N F O A B S T R A C T Keywords: Coronavirus disease 2019 COVID-19 Metformin Diabetes Treatment Background and aims: The coronavirus disease 2019 (COVID-19) pandemic has caused a significant impact on all aspects of life. One of the comorbidities associated with severe outcome and mortality of COVID-19 is diabetes. Metformin is one of the drugs which is most commonly used for the treatment of diabetes patients. This study aims to analyze the potential benefit of metformin use in reducing the mortality rate from COVID-19 infection. Methods: We systematically searched the Google Scholar database using specific keywords related to our aims until August 3rd, 2020. All articles published on COVID-19 and metformin were retrieved. Statistical analysis was done using Review Manager 5.4 software. Results: A total of 5 studies with a total of 6937 patients were included in our analysis. Our meta-analysis showed that metformin use is associated with reduction in mortality rate from COVID-19 infections [RR 0.54 (95% CI 0.32–0.90), p = 0.02, I2 = 54%, random-effect modelling]. Conclusion: Metformin has shown benefits in reducing the mortality rate from COVID-19 infections. Patients with diabetes should be advised to continue taking metformin drugs despite COVID-19 infection status.